Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 FDA Clears Tasso+ Lancet for Virtually Painless Blood Collection - Medical Product Outsourcing
OEM News

FDA Clears Tasso+ Lancet for Virtually Painless Blood Collection

First device to meet new FDA reclassification requirements for blood sampling devices.

Tasso has earned U.S. Food and Drug Administration (FDA) clearance for its Tasso+ lancet device for simple and virtually painless blood collection.
 
The single-use, patient-centric blood collection device is the first to earn Class I clearance as part of the new reclassification process for lancets. Tasso+ will we widely available across the U.S. in Q4 2022.
 
“With continued industry interest in decentralized clinical trials and diverse testing applications, demand for our high-quality, virtually painless, convenient blood collection solutions is at an all-time high,” Ben Casavant, Ph.D., CEO and co-founder of Tasso told the press. “This FDA Class II medical device clearance will help improve patient care by relieving traditional phlebotomy-related bottlenecks and enabling more individuals to get the tests they need at the time they are needed. We are excited to unlock a new wave of large commercial opportunities for the company and to lead the industry into the future of remote testing.”

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters